Loading clinical trials...
Loading clinical trials...
Tislelizumab in Combination With Pre-operative Chemoradiotherapy Versus SOC for Patients With Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: a Multicenter, Randomized, Open-label, Phase IIB Trial
Conditions
Interventions
Tislelizumab
S-1
+3 more
Locations
3
China
Wuhan Tongji Hospital
Wuhan, Hubei, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Shanxi Province Cancer Hospital
Taiyuan, Shanxi, China
Start Date
March 15, 2023
Primary Completion Date
February 28, 2027
Completion Date
August 31, 2027
Last Updated
April 19, 2023
NCT04550494
NCT04704661
NCT05489211
NCT04674267
NCT05702229
NCT07217704
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions